ABSTRACT purpose. To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis. Methods. 45 postmenopausal, osteoporotic women aged 57 to 79 (mean, 67) years underwent raloxifene treatment (60 mg/day) for 12 months. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months, whereas hip structure analysis (HSA) parameters of the femur (neck, intertrochanter, and shaft) were measured at baseline and 12 months using dual energy X-ray absorptiometry. The HSA parameters included areal bone mineral density (BMD), inner diameter, mean cortical thickness, crosssectional area, section modulus, and buckling ratio. Correlations between sNTX and HSA parameters were analysed using Pearson's R. results. At baseline, sNTX correlated inversely with BMD, cross-sectional area, mean cortical thickness, Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene
and section modulus, and positively with buckling ratio in the intertrochanter and shaft (but not the neck). These correlations were significant both crude and adjusted for age. After 12 months of raloxifene treatment, HSA parameters improved significantly for the intertrochanter and shaft only. Of the 3 femoral sites, only the change in sNTX at month 6 correlated positively with changes in the inner diameter at the intertrochanter at month 12 (r=0.303, p=0.045 adjusted for age). Changes in sNTX did not correlate with changes in any other parameters. conclusion. The surrogate markers for hip fracture including sNTX, BMD, and HSA parameters correlated significantly with each other. Improvement (decrease) of sNTX indicated reduction in bone resorption.
increases fracture risk. 1 Bone strength primarily reflects bone density and quality. Accelerated bone resorption increases fracture risk. [2] [3] [4] Biochemical markers of bone turnover may reflect underlying changes in bone histomorphometric parameters or bone mass. [5] [6] [7] [8] [9] Antiresorptive drugs such as raloxifene reduce the fracture risk by decreasing bone turnover. 10 Decreased bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) correlates with increased fracture risk, [11] [12] [13] but fracture reduction after treatment can only be partially explained by increased BMD. [14] [15] [16] Bone strength is governed by structural dimension and tissue material properties. The hip structure analysis (HSA) is applied to measure proximal femur geometry and strength using DXA. 17, 18 The HSA has demonstrated age trends, racial and gender differences, and treatment effects on patients with osteoporosis, [18] [19] [20] [21] [22] [23] [24] [25] [26] as well as age-related differences in structural geometry and strength of the femur. 27 Raloxifene and bisphosphonates (alendronate, risedronate) have positive effects on the structural geometry of the proximal femur in Japanese women with osteoporosis. 28, 29 We assessed correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis.
Materials and Methods
45 community-dwelling, ambulatory, postmenopausal, osteoporotic women aged 57 to 79 (mean, 67; standard deviation, 5) years were included. According to the Japanese diagnostic criteria, 30 osteoporosis was defined as a T-score (BMD) of <-2.5 or the presence of osteoporotic fractures. Those with a history of hip fracture, or any disease or medication known to affect bone metabolism were excluded.
All patients were given raloxifene (60 mg/ day) over the study period between April 2005 and March 2008. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months (it was not measured at 12 months owing to the Japanese health insurance policy), whereas HSA parameters of the femur were measused at baseline and 12 months using DXA. During scanning, a hip positioner system (OsteoDyne, Durham [NC], USA) was used to ensure consistent positioning of the legs (in abduction and 15º internal rotation). 31 DXA scans were first converted into bone mass images in which pixel values represent bone mass (in g/cm 2 ) using an automated program. The underlying principle is that a line of pixels traversing the bone axis is a projection of the corresponding cross section from which certain geometric properties can be derived. The femoral sites measured were: (1) the neck, which was defined as the narrowest width of the femoral neck; (2) the intertrochanter, which was defined as along the bisector of the shaft and femoral neck axes; and (3) the shaft, which was defined as at a distance of 1.5 times the minimum neck width, distal to the intersection of the neck and shaft axes. The HSA parameters 32, 33 included: (1) areal BMD (g/cm 2 ), (2) inner diameter (cm), (3) mean cortical thickness (cm), which was assumed to be a circular (for narrow neck or shaft) or an elliptical (intertrochanteric) annulus model of the crosssection, (4) cross-sectional area (cm 2 ), which was the surface area of bone tissue in the cross section after excluding soft-tissue (marrow) spaces, and an index of resistance to forces directed along the long axis of the bone, (5) section modulus (cm 3 ), which was an index of resistance to bending forces calculated as CSMI/ d max , where CSMI was the cross-sectional moment of inertia and dmax was the maximum distance from either bone edge to the centroid of the profile, and (6) buckling ratio, which was stable configurations of thin-walled tubes subjected to compressive loads and was estimated as the ratio of d max to the mean cortical thickness. Precision error for parameters at the neck, intertrochanter, and shaft ranged from 0.8% to 4.7%, with a mean of 2.2%. 27, 34 Correlations between sNTX and HSA parameters were analysed using Pearson's R, and were considered statistically significant at p<0.05. Correlations were adjusted for age, which strongly influences sNTX and HSA parameters.
results
The median sNTX at baseline was 15.3 nmol bone collagen equivalent (BCE)/l (reference range for Japanese healthy premenopausal women, 7.5-16.5 nmol BCE/l). 35 At baseline, sNTX correlated inversely with BMD, cross-sectional area, mean cortical thickness, and section modulus, and positively with buckling ratio in the intertrochanter and shaft (but not the neck) [ Table] . These correlations were significant both crude and adjusted for age.
After 6 months of raloxifene treatment, the median sNTX was 12.6 (nmol BCE/l) and the median percent change was -13.5%. After 12 months of raloxifene treatment, HSA parameters improved significantly for the intertrochanter and shaft only. In the intertrochanter, BMD, cross-sectional area, mean cortical thickness, and section modulus increased significantly by 3.77%, 3.94%, 4.59%, and 4.17%, respectively, whereas the buckling ratio decreased significantly by 4.27%. Results at the shaft were qualitatively similar to those at the intertrochanter, except for the inner diameter that significantly decreased by 3.87% (Table) . Of the 3 femoral sites, only the change in sNTX at month 6 positively correlated with changes in the inner diameter at the intertrochanter at month 12 (r=0.303, p=0.045 adjusted for age). Changes in sNTX did not correlate with changes in any other parameters (Table) .
discussion
In one study, the sNTX correlated significantly with the HSA parameters at the intertrochanter only, and thus only the risk of trochanteric fractures could be discerned based on BMD. 36 Trochanteric fractures are strongly dependent on osteofragility (osteoporosis), compared to neck fractures. 36 In our study, the sNTX correlated significantly with the inner diameter at the intertrochanter only (r=0.303, p=0.045 adjusted for age), probably because (1) raloxifene did not strongly decrease bone resorption, compared to bisphosphonates, 37 the range of percent changes in sNTX was narrow and did not attain significance. Nonetheless, the effect of raloxifene on HSA parameters was similar to that of bisphosphonates. 29 (2) The strength index (e.g. section modulus, buckling ratio, cross-sectional area) was calculated by the combination of several parameters (e.g. outer diameter, inner diameter, d max , mean cortical thickness). Thus, changes in each parameter were offset by calculating the strength index. (3) A placebo group was lacking. Although sNTX and HSA parameters were measured 6 and 12 months after raloxifene therapy, respectively, these periods (6 and 12 months) were too short for normal changes to occur and might be negligible. (4) All outcomes measured were surrogate markers; it was ideal to evaluate the incidence of hip fracture. However, low incidence of hip fractures would have necessitated enrollment of large numbers of patients. In one observational study, there was no significant difference in hip fracture incidence between patients treated with risedronate, raloxifene, and alendronate. 
